Comparative Pharmacology
Head-to-head clinical analysis: EXALGO versus SYNALGOS DC A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXALGO versus SYNALGOS DC A.
EXALGO vs SYNALGOS-DC-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; inhibits ascending pain pathways and alters pain perception and emotional response to pain.
SYNALGOS-DC-A contains dihydrocodeine, which is a semisynthetic opioid agonist; aspirin, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes; and caffeine, a central nervous system stimulant. Dihydrocodeine binds to mu-opioid receptors in the central nervous system to produce analgesia. Aspirin irreversibly acetylates COX-1 and COX-2, reducing prostaglandin synthesis. Caffeine enhances analgesia via adenosine receptor antagonism and possibly by increasing drug absorption.
Initial: 8 mg orally every 24 hours for opioid-naive patients; titration based on response; maximum 32 mg daily.
1-2 capsules orally every 4-6 hours as needed for pain; each capsule contains dihydrocodeine bitartrate 16 mg, acetaminophen 356.4 mg, and caffeine 30 mg.
None Documented
None Documented
Terminal elimination half-life: approximately 15-18 hours in healthy adults. Steady state is achieved by 3-5 days. In patients with hepatic impairment, half-life may be prolonged up to 24-27 hours.
Propoxyphene: 6-12 hours; norpropoxyphene: 30-36 hours; clinical context: prolonged with hepatic impairment, age >60 years, and renal dysfunction; accumulation of norpropoxyphene may cause cardiotoxicity
Renal: primarily as hydromorphone-3-glucuronide and unchanged drug (~40% as glucuronide conjugates, ~3% as unchanged hydromorphone). Fecal: minimal. Total renal clearance accounts for ~50% of drug elimination.
Renal: ~70-80% as free and conjugated propoxyphene; norpropoxyphene is renally eliminated; biliary: 10-20%; fecal: <10%
Category C
Category C
Opioid Analgesic
Opioid Analgesic